Venkatraman Radhakrishnan1, Anand Raja2, Manikandan Dhanushkodi3, T S Ganesan3, G Selvaluxmy4, T G Sagar3. 1. Department of Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamilnadu, India. venkymd@gmail.com. 2. Department of Surgical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamilnadu, India. 3. Department of Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamilnadu, India. 4. Department of Radiotherapy, Cancer Institute (WIA), Adyar, Chennai, Tamilnadu, India.
Abstract
OBJECTIVES: Management of neuroblastoma, especially high-risk (HR) disease is difficult in a resource-limited setting. There is a paucity of literature on outcomes of patients treated in India. The present study was conducted to analyse the clinical profile, treatment, and outcomes of patients with neuroblastoma treated at authors' centre. METHODS: The study was a retrospective analysis of newly diagnosed patients with neuroblastoma treated at authors' centre between 2000 to 2017. The International Neuroblastoma Staging System and risk grouping were used to classify patients as low-risk (LR), intermediate-risk (IR) and high-risk (HR). Treatment was individualised and risk-adapted. Kaplan-Meier method was used to calculate the event-free survival (EFS) and overall survival (OS). RESULTS: The study included 85 patients with a median age of 4 y and 67% were males. Malnutrition was observed in 55% of patients. Adrenal gland was the most common site in 75% patients followed by mediastinum in 12%. LR was observed in 7/85 (8%) patients, IR 20/85 (24%) and HR in 58/85 (68%) patients. The CCG-3891 protocol was used to treat 80% of the patients. Autologous stem cell transplantation (ASCT) was performed in 32% of HR patients. The median follow-up was 16.6 mo. The median EFS and OS for all patients were 19.2 mo and 26.9 mo respectively and the 3 y EFS and OS was 36% and 47% respectively. The 3y EFS for LR, IR and HR patients was 100%, 54%, and 18.9% respectively (P < 0.001) and for OS was 100%, 77%, and 34% respectively (P = 0.002). On multivariate analysis, a hemoglobin less than 10 g% predicted inferior EFS (P = 0.002) and OS (p = 0.005) for all patients. For patients with high-risk disease, on multivariate analysis, hemoglobin (P = 0.002) and 13-Cis Retinoic acid maintenance (P = 0.002) predicted EFS and only radiotherapy to the primary (P = 0.01) predicted OS. Only 4/19 (21%) are alive and in remission post ASCT. CONCLUSIONS: Majority of patients with neuroblastoma presented to authors' centre with advanced disease. Survival outcomes of patients with LR disease are excellent. However, patients with HR disease have poor outcomes despite multimodality management. Non-availability of N-MYC testing in few patients could have falsely down-staged them to IR from HR. A low hemoglobin at diagnosis is a poor predictor of outcome.
OBJECTIVES: Management of neuroblastoma, especially high-risk (HR) disease is difficult in a resource-limited setting. There is a paucity of literature on outcomes of patients treated in India. The present study was conducted to analyse the clinical profile, treatment, and outcomes of patients with neuroblastoma treated at authors' centre. METHODS: The study was a retrospective analysis of newly diagnosed patients with neuroblastoma treated at authors' centre between 2000 to 2017. The International Neuroblastoma Staging System and risk grouping were used to classify patients as low-risk (LR), intermediate-risk (IR) and high-risk (HR). Treatment was individualised and risk-adapted. Kaplan-Meier method was used to calculate the event-free survival (EFS) and overall survival (OS). RESULTS: The study included 85 patients with a median age of 4 y and 67% were males. Malnutrition was observed in 55% of patients. Adrenal gland was the most common site in 75% patients followed by mediastinum in 12%. LR was observed in 7/85 (8%) patients, IR 20/85 (24%) and HR in 58/85 (68%) patients. The CCG-3891 protocol was used to treat 80% of the patients. Autologous stem cell transplantation (ASCT) was performed in 32% of HR patients. The median follow-up was 16.6 mo. The median EFS and OS for all patients were 19.2 mo and 26.9 mo respectively and the 3 y EFS and OS was 36% and 47% respectively. The 3y EFS for LR, IR and HR patients was 100%, 54%, and 18.9% respectively (P < 0.001) and for OS was 100%, 77%, and 34% respectively (P = 0.002). On multivariate analysis, a hemoglobin less than 10 g% predicted inferior EFS (P = 0.002) and OS (p = 0.005) for all patients. For patients with high-risk disease, on multivariate analysis, hemoglobin (P = 0.002) and 13-Cis Retinoic acid maintenance (P = 0.002) predicted EFS and only radiotherapy to the primary (P = 0.01) predicted OS. Only 4/19 (21%) are alive and in remission post ASCT. CONCLUSIONS: Majority of patients with neuroblastoma presented to authors' centre with advanced disease. Survival outcomes of patients with LR disease are excellent. However, patients with HR disease have poor outcomes despite multimodality management. Non-availability of N-MYC testing in few patients could have falsely down-staged them to IR from HR. A low hemoglobin at diagnosis is a poor predictor of outcome.
Authors: David L Baker; Mary L Schmidt; Susan L Cohn; John M Maris; Wendy B London; Allen Buxton; Daniel Stram; Robert P Castleberry; Hiroyuki Shimada; Anthony Sandler; Robert C Shamberger; A Thomas Look; C Patrick Reynolds; Robert C Seeger; Katherine K Matthay Journal: N Engl J Med Date: 2010-09-30 Impact factor: 91.245
Authors: André Oberthuer; Dilafruz Juraeva; Barbara Hero; Ruth Volland; Carolina Sterz; Rene Schmidt; Andreas Faldum; Yvonne Kahlert; Anne Engesser; Shahab Asgharzadeh; Robert Seeger; Miki Ohira; Akira Nakagawara; Paola Scaruffi; Gian Paolo Tonini; Isabelle Janoueix-Lerosey; Olivier Delattre; Gudrun Schleiermacher; Jo Vandesompele; Frank Speleman; Rosa Noguera; Marta Piqueras; Jean Bénard; Alexander Valent; Smadar Avigad; Isaac Yaniv; Richard G Grundy; Monika Ortmann; Chunxuan Shao; Manfred Schwab; Roland Eils; Thorsten Simon; Jessica Theissen; Frank Berthold; Frank Westermann; Benedikt Brors; Matthias Fischer Journal: Clin Cancer Res Date: 2014-09-17 Impact factor: 12.531
Authors: Steven G DuBois; Rajen Mody; Arlene Naranjo; Collin Van Ryn; Douglas Russ; Derek Oldridge; Susan Kreissman; David L Baker; Marguerite Parisi; Barry L Shulkin; Harrison Bai; Sharon J Diskin; Vandana Batra; John M Maris; Julie R Park; Katherine K Matthay; Gregory Yanik Journal: Pediatr Blood Cancer Date: 2017-04-06 Impact factor: 3.167
Authors: Tom Monclair; Garrett M Brodeur; Peter F Ambros; Hervé J Brisse; Giovanni Cecchetto; Keith Holmes; Michio Kaneko; Wendy B London; Katherine K Matthay; Jed G Nuchtern; Dietrich von Schweinitz; Thorsten Simon; Susan L Cohn; Andrew D J Pearson Journal: J Clin Oncol Date: 2008-12-01 Impact factor: 44.544
Authors: G M Brodeur; J Pritchard; F Berthold; N L Carlsen; V Castel; R P Castelberry; B De Bernardi; A E Evans; M Favrot; F Hedborg Journal: J Clin Oncol Date: 1993-08 Impact factor: 44.544
Authors: Nehal S Parikh; Scott C Howard; Guillermo Chantada; Trijn Israels; Mohammed Khattab; Patricia Alcasabas; Catherine G Lam; Lawrence Faulkner; Julie R Park; Wendy B London; Katherine K Matthay Journal: Pediatr Blood Cancer Date: 2015-03-21 Impact factor: 3.167